Lanean...
Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM
BACKGROUND: Dapagliflozin is a sodium–glucose co transporter-2 inhibitor that proved efficacy in reduction of blood glucose level through extrusion of glucose in urine. It is used in treatment of type 2 diabetes mellitus (T2DM). It also has reported cardiovascular and renal benefits in patients with...
Gorde:
| Argitaratua izan da: | Ther Adv Endocrinol Metab |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
SAGE Publications
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970182/ https://ncbi.nlm.nih.gov/pubmed/33796252 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042018821995364 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|